- Home
- ZURA vs STHO Comparison
ZURA vs STHO Comparison
Compare ZURA & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- STHO
- Stock Information
- Founded
- ZURA 2022
- STHO N/A
- Country
- ZURA United States
- STHO United States
- Employees
- ZURA N/A
- STHO N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- STHO Real Estate
- Sector
- ZURA Health Care
- STHO Real Estate
- Exchange
- ZURA Nasdaq
- STHO Nasdaq
- Market Cap
- ZURA 137.2M
- STHO 112.7M
- IPO Year
- ZURA N/A
- STHO N/A
- Fundamental
- Price
- ZURA $4.16
- STHO $7.98
- Analyst Decision
- ZURA Buy
- STHO
- Analyst Count
- ZURA 9
- STHO 0
- Target Price
- ZURA $11.00
- STHO N/A
- AVG Volume (30 Days)
- ZURA 3.9M
- STHO 42.3K
- Earning Date
- ZURA 11-06-2025
- STHO 11-04-2025
- Dividend Yield
- ZURA N/A
- STHO N/A
- EPS Growth
- ZURA N/A
- STHO N/A
- EPS
- ZURA N/A
- STHO N/A
- Revenue
- ZURA N/A
- STHO $113,989,000.00
- Revenue This Year
- ZURA N/A
- STHO N/A
- Revenue Next Year
- ZURA N/A
- STHO N/A
- P/E Ratio
- ZURA N/A
- STHO N/A
- Revenue Growth
- ZURA N/A
- STHO N/A
- 52 Week Low
- ZURA $0.97
- STHO $6.06
- 52 Week High
- ZURA $5.07
- STHO $13.50
- Technical
- Relative Strength Index (RSI)
- ZURA 84.19
- STHO 38.46
- Support Level
- ZURA $2.07
- STHO $8.01
- Resistance Level
- ZURA $2.35
- STHO $8.39
- Average True Range (ATR)
- ZURA 0.21
- STHO 0.27
- MACD
- ZURA 0.20
- STHO -0.08
- Stochastic Oscillator
- ZURA 95.42
- STHO 19.20
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.